Occurrence of components of fibrinolytic pathways in situ in laryngeal cancer

Seminars in Thrombosis and Hemostasis

Volumn 29, Issue 3, 2003, Pages 317-320

  Wojtukiewicz, Marek Z ^a   Sierko, Ewa ^a   Zacharski, Leo R ^b,c   Rózanska Kudelska, Malgorzata ^a   Zimnoch, Lech ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c Department of Veterans Affairs Regional Office White River Junction   (United States)

Author keywords

Blood coagulation; Fibrinolysis; Laryngeal cancer

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 13A; BLOOD CLOTTING FACTOR 7; FIBRIN; FIBRINOGEN; LOW MOLECULAR WEIGHT UROKINASE PLASMINOGEN ACTIVATOR; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN ACTIVATOR INHIBITOR 3; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; BLOOD CLOTTING; CARCINOMA CELL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONNECTIVE TISSUE; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBRINOLYSIS; HOST TUMOR INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; LARYNX CARCINOMA; MICROVASCULATURE; PRIORITY JOURNAL; SQUAMOUS CELL; STAINING; TUMOR CELL;

FIBRINOLYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; PLASMINOGEN; PLASMINOGEN INACTIVATORS; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037757856     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40970     Document Type: Article

References (31)

1. Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Semin Thromb Hemost 1998;24:93-109
2. Bromberg ME, Capello M. Cancer and blood coagulation: molecular aspects. Cancer J 1999;5:132-138
3. Wojtukiewicz MZ, Rucinska M, Zimnoch L, et al. Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb Res 2000;97:335-342
4. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 1990;65:481-485
5. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990;93:516-521
6. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 1990;10:579-582
7. Wojtukiewicz MZ, Zacharski LR, Rucinska M, et al. Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma. Thromb Haemost 1999;82:1659-1662
8. Wojtukiewicz MZ, Rucinska M, Zacharski LR, et al. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost 2001;86:1416-1420
9. Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992;18:104-116
10. Constantini V, Zacharski LR, Memoli VA, et al. Occurence of components of fibrinolysis pathways in situ in neoplasmatic human breast tissue. Cancer Res 1991;51:354-358
11. Ornstein DL, Constantini V, Zacharski LR, et al. Coexistent macrophage procoagulant and tumor cell plasminogen activator in adenocarcinoma and squamous cell carcinoma of the lung. Cancer 1991;68:1061-1067
12. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Indirect activation of blood coagulation in colon cancer. Thromb Haemost 1989;62:1062-1066
13. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer 1991;67:1377-1383
14. Nasyrov VA, Osmonowa RO, Rachkol AG. State of the hemostasis system in patients with malignant III-stage neoplasms of the maxilla and larynx. Vestn Otorinolaringol 1991;5:12-15
15. Sato Y, Mukai K, Watanabe S, Goto M, Shimosato Y. The AMeX method. The simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am J Pathol 1986;125:431-435
16. Hsu S, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580
17. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999;82:259-270
18. Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in neoplasms. Neoplasia 2001;51:93-103
19. Carroll VA, Binder BR. The role of the plasminogen activation system in cancer. Semin Thromb Haemost 1999;25:183-197
20. Lentschener C, Li H, Franco D, et al. Intraoperatively-administered aprotinin and survival after elective liver resection for colorectal cancer metastasis. A preliminary study. Fibrinolysis Proteolysis 1999;13:39-45
21. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998;80:10-23
22. Pasini F, Brentani MM, Kowalski LP, Federico MH. Transforming growth factor-1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa. Head Neck 2001;23:725-732
23. Parolini S. Flagiello D, Cinquetti A, et al. Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. Br J Cancer 1996;74:1168-1174
24. Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996;78:487-492
25. Pyke C, Kristensen P, Ralfkiaer E, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138:1059-1067
26. Bianchi E, Cohen RL, Thor AT, et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994;54:861-866
27. De Vries TJ, Quax PHA, Denijn M, et al. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994;144:70-81
28. Pedersen H, Grondahl-Hansen J, Francis D, et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994;54:120-123
29. Cohen RL, Xi X-P, Crowley CW, et al. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood 1991;78:479-487
30. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 1999;82:298-304
31. Homer JJ, Greenman J, Stafford ND. The expression of vascular endothelial growth factor (VEGF) and VEGF-C in early laryngeal cancer: relationship with radioresistance. Clin Otolaryngol 2001;26:498-504